Duchenne Muscular Dystrophy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Duchenne Muscular Dystrophy stocks.

Duchenne Muscular Dystrophy Stocks Recent News

Date Stock Title
May 5 SRPT Earnings Beat: Sarepta Therapeutics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
May 3 SRPT Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
May 3 DYN Dyne Therapeutics GAAP EPS of -$0.81 misses by $0.01
May 2 DYN Dyne Therapeutics Reports First Quarter 2024 Financial ResultsĀ and Recent Business Highlights
May 2 SRPT Sarepta Therapeutics to Benefit as Regulatory Review on DMD Therapy Picks Up, Morgan Stanley Says
May 2 SRPT Sarepta Elevidys accelerated approval criticized by ICER exec
May 2 SMMT Summit Therapeutics Inc. (NASDAQ:SMMT) Q1 2024 Earnings Call Transcript
May 2 SRPT Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y
May 2 SRPT Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Call Transcript
May 2 WVE Wave Life Sciences First Quarter 2024 Financial Results Scheduled for May 9, 2024
May 2 SRPT Q1 2024 Sarepta Therapeutics Inc Earnings Call
May 2 SRPT Sarepta Therapeutics Inc (SRPT) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
May 2 SMMT Summit Therapeutics Inc (SMMT) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
May 2 SMMT Q1 2024 Summit Therapeutics Inc Earnings Call
May 2 SMMT Summit Therapeutics Inc. (SMMT) Q1 2024 Earnings Call Transcript
May 1 SRPT Sarepta Therapeutics (SRPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
May 1 SRPT Sarepta Therapeutics (SRPT) Q1 2024 Earnings Call Transcript
May 1 SRPT Sarepta Therapeutics, Inc. (SRPT) Q1 2024 Earnings Call Transcript
May 1 SRPT Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Beat Estimates
May 1 SRPT Sarepta Therapeutics jumps 5% on Q1 beats
Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a severe type of muscular dystrophy. The symptom of muscle weakness usually begins around the age of four in boys and worsens quickly. Typically muscle loss occurs first in the upper legs and pelvis followed by those of the upper arms. This can result in trouble standing up. Most are unable to walk by the age of 12. Affected muscles may look larger due to increased fat content. Scoliosis is also common. Some may have intellectual disability. Females with a single copy of the defective gene may show mild symptoms.The disorder is X-linked recessive. About two thirds of cases are inherited from a person's mother, while one third of cases are due to a new mutation. It is caused by a mutation in the gene for the protein dystrophin. Dystrophin is important to maintain the muscle fiber's cell membrane. Genetic testing can often make the diagnosis at birth. Those affected also have a high level of creatine kinase in their blood.Although there is no known cure, physical therapy, braces, and corrective surgery may help with some symptoms. Assisted ventilation may be required in those with weakness of breathing muscles. Medications used include steroids to slow muscle degeneration, anticonvulsants to control seizures and some muscle activity, and immunosuppressants to delay damage to dying muscle cells.DMD affects about one in 5,000 males at birth. It is the most common type of muscular dystrophy. The average life expectancy is 26; however, with excellent care, some may live into their 30s or 40s. Gene therapy, as a treatment, is in the early stages of study in humans.

Browse All Tags